FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Young Teresa L. (Last) (First) (Middle) C/O SERES THERAPEUTICS, INC. 200 SIDNEY STREET (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)				3. 02 4.	2. Issuer Name and Ticker or Trading Symbol Seres Therapeutics, Inc. [MCRB] 3. Date of Earliest Transaction (Month/Day/Year) 02/03/2023 4. If Amendment, Date of Original Filed (Month/Day/Year)						6. li	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) See Remarks 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
				ansaction hth/Day/Y	2A. Deemed Execution Date,		3. Transactic Code (Ins 8) Code V	4. Securi Disposed 5) Amount	(A) or (D)	Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	4. Transaction Code (Instr		5. Number of		6. Date Exercisable an Expiration Date (Month/Day/Year)				8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4		Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Restricted Stock Units	(1)	02/03/2023		A		42,500		(2)	(2)	Common Stock	42,500	\$0.00	42,500		D		
Restricted Stock Units	(1)	02/03/2023		A		85,000		(3)	(3)	Common Stock	85,000	\$0.00	85,000		D		
Stock Option (Right to Buy)	\$5.5	02/03/2023		A		85,000		(4)	02/02/2033	Common Stock	85,000	\$0.00	85,000		D		

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- 2. The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments
- 3. The restricted stock units will vest and settle as to 100% of the restricted stock units on August 3, 2024.
- 4. The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Remarks:

EVP, Chief Commercial & Strategy Officer

/s/ Thomas J. DesRosier, attorney-in-fact for Teresa L.

02/07/2023

Young

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.